Cipla’s wholly owned subsidiary in UK -- Cipla (EU) has agreed to acquire an additional 19.16% stake in Cipla Maroc SA, joint venture and subsidiary of Cipla EU in Morocco. Cost of acquisition will be around Moroccan dirham 102.90 million. Upon completion of acquisition, Cipla EU will hold 79.16% stake in the JV Co and balance 20.84% stake will be held by Cooper Pharma.
Cipla Maroc SA was incorporated in 2015, in Morocco, as a joint venture between Cipla EU (60%), The Pharmaceutical Institute (PHI) (24.20%) and Societe Marocaine De Cooperation Pharmaceutique (Cooper Pharma) (15.80%) for the purpose of manufacturing, marketing and distribution of pharmaceutical products in Morocco.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1670.00 |
| Dr. Reddys Lab | 1236.40 |
| Cipla | 1238.25 |
| Zydus Lifesciences | 942.05 |
| Lupin | 2330.35 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: